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The perfluoroalkyl acids (PFAAs) are a family 
of synthetic, highly stable perfluorinated com-
pounds with a wide range of uses in industrial 
and consumer products, from stain- and water-
resistant coatings for carpets and fabrics to fast-
food contact materials, fire-resistant foams, 
paints, and hydraulic fluids (Organisation for 
Economic Co-operation and Development 
2005). The carbon–fluoride bonds that char-
acterize PFAAs and make them useful as sur-
factants are highly stable, and recent reports 
indicate the widespread persistence of certain 
PFAAs in the environment and in wildlife and 
human populations globally (Fromme et al. 
2009; Giesy and Kannan 2001; Lau et al. 
2007; Saito et al. 2004). Two of the PFAAs 
of most concern are the eight-carbon–chain 
perfluorooctane sulfonate (PFOS) and perfluo-
rooctanoic acid (PFOA, also known as C8).
Most persistent organic pollutants are 
lipophilic and accumulate in fatty tissues, but 
PFOS and PFOA are both lipo- and hydro-
phobic, and after absorption will bind to pro-
teins in serum rather than accumulating in 
lipids (Hundley et al. 2006; Jones et al. 2003). 
The renal clearance of PFOA and PFOS is neg-
ligible in humans, leading to reported half-lives 
in blood serum of 3.8 and 5.4 years for PFOA 
and PFOS, respectively (Olsen et al. 2007). 
Human biomonitoring of the general popula-
tion in various countries has shown that, in 
addition to the near ubiquitous presence of 
PFOS and PFOA in blood, these may also be 
present in breast milk, liver, seminal fluid, and 
umbilical cord blood (Lau et al. 2007).
Extensive laboratory studies of the toxicol-
ogy of PFOA and PFOS have reported enlarge-
ment of the liver, modulation of sex hormone 
homeostasis, developmental and immune 
system toxicity, hypolipidemia, and reduced 
body weight in rodent and nonhuman primate 
models [reviewed by Lau et al. (2004, 2007)]. 
Research interest has focused on the ability of 
these compounds to bind to nuclear receptors, 
including the peroxisome proliferator–  activating 
receptor (PPARα), and to disrupt serum protein 
ligand binding (Luebker et al. 2002), highlight-
ing PFOA and PFOS as potential endocrine 
disruptors (Jensen and Leffers 2008).
Endocrine systems that may be targets of 
endocrine-disrupting chemicals include the 
hypothalamus–pituitary–thyroid (HPT) axis 
(Boas et al. 2006). Thyroid hormone is essential 
for the normal physiologic function of nearly all 
mammalian tissues. Thyroid hormone status is 
controlled by a well-established feedback mech-
anism, in which thyroid-stimulating hormone 
(TSH) stimulates the thyroid to synthesize 
thyroxine (T4), which is then converted to 
the biologically active triiodothyronine (T3). 
The rate of release of TSH is regulated by the 
hypothalamus as well as by the circulating levels 
of T3 and T4. Therefore, multiple physiologic 
steps, including hormone biosynthesis, trans-
port, metabolism, and action on target cells, are 
required for thyroid hormone homeostasis.
Numerous studies have now shown PFAAs 
to impair thyroid hormone homeostasis in ani-
mal studies. Depression of serum T4 and T3 
in PFOS-exposed rats has been reported by 
several authors (Lau et al. 2003; Luebker et al. 
2005; Seacat et al. 2003), without the concom-
itant increase in TSH that would be expected 
through feedback stimulation. Earlier mecha-
nistic studies of structurally related perfluo-
rodecanoic acid showed that it could reduce 
serum thyroid hormone levels apparently by 
reducing the responsiveness of the HPT axis 
and by displacing circulating thyroid hor-
mones from their plasma protein-binding sites 
(Gutshall et al. 1989). Although circulating 
hormone levels were depressed, the activities of 
thyroid hormone–sensitive liver enzymes were 
elevated, suggesting that functional hypothy-
roidism was not occurring. A similar mecha-
nism for PFOS has been hypothesized (Chang 
et al. 2007). A recent study of the mechanisms 
involved in PFOS-induced hypothyroxinemia 
in rats has indicated that increased conjuga-
tion of T4 in the liver, catalyzed by the hepatic 
enzyme uridine diphosphoglucuronosyl trans-
ferase (UGT1A1), and increased thyroidal con-
version of T4 to T3 by type 1 deiodinase may 
be partly responsible for the effects (Yu et al. 
2009). Taken together, these findings suggest 
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Ba c k g r o u n d: Perfluorooctanoic acid (PFOA, also known as C8) and perfluorooctane sulfonate 
(PFOS) are stable compounds with many industrial and consumer uses. Their persistence in the 
environment plus toxicity in animal models has raised concern over low-level chronic exposure 
effects on human health.
oBjectives: We estimated associations between serum PFOA and PFOS concentrations and thy-
roid disease prevalence in representative samples of the U.S. general population.
Me t h o d s : Analyses of PFOA/PFOS versus disease status in the National Health and Nutrition 
Examination Survey (NHANES) for 1999–2000, 2003–2004, and 2005–2006 included 3,974 
adults with measured concentrations for perfluorinated chemicals. Regression models were adjusted 
for age, sex, race/ethnicity, education, smoking status, body mass index, and alcohol intake.
re s u l t s: The NHANES-weighted prevalence of reporting any thyroid disease was 16.18% (n = 292) 
in women and 3.06% (n = 69) in men; prevalence of current thyroid disease with related medication 
was 9.89% (n = 163) in women and 1.88% (n = 46) in men. In fully adjusted logistic models, women 
with PFOA ≥ 5.7 ng/mL [fourth (highest) population quartile] were more likely to report current 
treated thyroid disease [odds ratio (OR) = 2.24; 95% confidence interval (CI), 1.38–3.65; p = 0.002] 
compared with PFOA ≤ 4.0 ng/mL (quartiles 1 and 2); we found a near significant similar trend in 
men (OR = 2.12; 95% CI, 0.93–4.82; p = 0.073). For PFOS, in men we found a similar association 
for those with PFOS ≥ 36.8 ng/mL (quartile 4) versus ≤ 25.5 ng/mL (quartiles 1 and 2: OR for treated 
disease = 2.68; 95% CI, 1.03–6.98; p = 0.043); in women this association was not significant. 
co n c l u s i o n s: Higher concentrations of serum PFOA and PFOS are associated with current thy-
roid disease in the U.S. general adult population. More work is needed to establish the mechanisms 
involved and to exclude confounding and pharmacokinetic explanations.
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that the effects of PFAAs on thyroid hormone 
physiology are multiple and complex.
Extrapolations from animal laboratory 
studies such as these to an estimation of the 
risks posed by PFOA and PFOS to thyroid 
function in humans are complicated by the 
extreme variations reported in their toxico-
kinetic profile between species (Johnson et al. 
1979; Olsen et al. 2007). The extremely long 
half-lives of PFOA and PFOS in humans con-
trast with the relatively rapid elimination seen 
in animal models (e.g., serum half-life of PFOS 
in rats is around 100 days) (Hundley et al. 
2006), drawing attention to the potential risks 
to human health. Disruption to thyroid hor-
mone balance was not found in previous stud-
ies of community exposure to PFOA (Emmett 
et al. 2006; Olsen et al. 2003b) or PFOS 
(Inoue 2004). Modest associations between 
PFOA and thyroid hormones (negative for 
free T4 and positive for T3) were reported in 
506 PFOA production workers across three 
production facilities (Olsen and Zobel 2007); 
there were no associations between TSH or T4 
and PFOA, and the free hormone levels were 
within the normal reference range.
Given the evidence from animal studies 
of thyroid hormone imbalance and the varied 
epidemiologic results from community and 
occupational exposures, we aimed to explore 
the hypothesis that higher serum PFOA and 
PFOS concentrations would be associated 
with thyroid disease in the general adult popu-
lation. The environmental chemical biomoni-
toring program of the U.S. Centers for Disease 
Control and Prevention, using samples from 
the U.S. National Health and Nutrition 
Examination Survey (NHANES), provides 
large-scale data on serum PFAA concentra-
tions in population-representative samples. In 
this study we used these data to estimate asso-
ciations between PFOA/PFOS concentrations 
and thyroid disease in representative samples 
of the U.S. general population. 
Methods
Study population. Data were from three inde-
pendent cross-sectional waves of NHANES: 
1999–2000, 2003–2004, and 2005–2006. 
NHANES surveys assess the health and diet of 
the noninstitutionalized civilian population of 
the United States and are administered by the 
National Center for Health Statistics (NCHS). 
The study protocol for NHANES was approved 
by the NCHS Institutional Review Board.
Assessment of PFOA/PFOS concentrations. 
Solid-phase extraction coupled to high-perfor-
mance liquid chromatography/turbo ion spray 
ionization/tandem mass spectrometry with 
isotope-labeled internal standards was used for 
the detection of PFOA and PFOS, with a limit 
of detection of 0.2 ng/mL (Kuklenyik et al. 
2005). The laboratory methods and compre-
hensive quality control system were consistent 
in each NHANES wave, and documenta-
tion for each wave is available (NCHS 2009; 
NHANES 2006, 2007).
Serum polyfluorinated chemicals (PFCs) 
were measured in a one-third representative 
random subset of persons ≥ 12 years of age in 
each NHANES wave. Data from individuals 
< 20 years of age were excluded, because ques-
tions relating to disease prevalence were asked 
only for adults.
Disease outcomes. In all NHANES waves, 
adult respondents were asked about physician-
diagnosed diseases. Associations were exam-
ined between PFOA and PFOS concentrations 
and thyroid disease outcomes. Individuals were 
asked whether they had ever been told by a 
doctor or health professional that they had a 
thyroid problem (in the 1999–2000 survey 
the questions related to goiter and other thy-
roid conditions) and whether they still had the 
condition. We further defined thyroid disease 
by considering those people who said they cur-
rently had thyroid disease and were taking any 
thyroid-related medication, including levothy-
roxine, liothyronine, “thyroid desiccated,” and 
“thyroid drugs unspecified” for hypothyroid-
ism and propylthiouracil and methimazole for 
hyperthyroidism. No details were available on 
specific thyroid disease diagnosis, and the PFC 
samples did not overlap with the thyroid hor-
mone measurement subsamples in NHANES.
To assess disease specificity, associations 
were examined between PFOA and the other 
NHANES disease categories elicited: ischemic 
heart disease (combining any diagnoses of coro-
nary heart disease, angina, and/or heart attack), 
diabetes, arthritis, current asthma, chronic 
obstructive pulmonary disease (COPD; bron-
chitis or emphysema), and current liver disease.
Statistical analysis. NHANES uses a com-
plex cluster sample design with some demo-
graphic groups (including less-privileged 
socioeconomic groups and Mexican Americans) 
oversampled to ensure adequate representation. 
Prevalence estimates and models were therefore 
survey-weighted using the NHANES primary 
sampling unit, strata, and population weights, 
unless otherwise stated.
Multivariate logistic regression modeling 
was used to estimate odds ratios (ORs) of thy-
roid disease outcomes by quartile of PFOA and 
PFOS concentrations, and associations of other 
physician-diagnosed diseases. Because thy-
roid disease prevalence is markedly higher in 
women, we used sex-specific models. Because 
the distribution of PFC concentrations is 
skewed (with most people having relatively low 
exposures and with considerably more variance 
at the higher exposure end), all available data 
were pooled, and PFOA and PFOS concentra-
tions were divided into population-weighted 
quartiles. Using the Hsieh method (Hsieh 
et al. 1998), our estimated power to detect an 
association of OR ≥ 1.8 with current treated 
disease comparing the top PFOA quartile 
(Q4) with bottom quartile (Q1) is 67% in 
women. Combining the lowest two quartiles 
(Q1 and Q2) into a larger control group pro-
vides 80% power. The corresponding mini-
mum detectable effect size in men is OR > 2.9. 
Assumptions for the power calculations include 
a significance level of 5% and a multiple cor-
relation coefficient of 0.2 relating PFOA expo-
sure to potential confounders.
Models were adjusted for the follow-
ing potential confounding factors: year of 
NHANES study; age; sex; race/ethnicity, from 
self-description and categorized into Mexican 
American, other Hispanic, non-Hispanic 
white, non-Hispanic black, and other race 
(including multiracial); education, catego-
rized into less than high school, high school 
diploma (including GED), more than high 
school, and unknown education; smoking 
(from self-reported status asked for those ≥ 20 
years of age), categorized into never smoked, 
former smoker, smoking some days, smoking 
every day, and unknown smoking status; body 
mass index (BMI; weight in kilograms divided 
by the square of measured height in meters), 
categorized into underweight (BMI < 18.5), 
recommended weight (BMI = 18.5–24.9), 
overweight (BMI = 25.0–29.9), obese (BMI 
= 30.0–34.9), and unknown BMI; and alco-
hol consumption (in adults ≥ 20 years of age, 
based on responses to the question “In the past 
12 months, on those days that you drank alco-
holic beverages, on the average day, how many 
drinks did you have?”), categorized into 0, 1, 
2, 3, 4, and ≥ 5 drinks per day, and unknown 
alcohol consumption. Regression analyses were 
conducted using STATA/SE (version 10.1; 
StataCorp LP, College Station, TX, USA).
Results
Serum concentrations of PFOA were avail-
able for n = 3,974 individuals ≥ 20 years of 
age from NHANES waves 1999–2000 (n = 
1,040), 2003–2004 (n = 1,454), and 2005–
2006 (n = 1,480). In analyses adjusted for age, 
sex, NHANES wave, and ethnicity, mean 
levels of PFOA were higher in men than in 
women [by 0.76 ng/mL; 95% confidence 
interval (CI), 0.73–0.80; p < 0.0001], and we 
found significant differences between ethnic 
groups (Table 1). Individuals with more edu-
cation had higher PFOA levels (highest vs. 
lowest education: 1.1 ng/mL difference; 95% 
CI, 1.03–1.19 ng/mL difference; p = 0.008). 
Increased alcohol consumption levels were also 
associated with higher PFOA concentrations 
(e.g., those having five or more drinks per day 
had mean PFOA levels 1.24 ng/mL higher 
than nondrinkers; 95% CI, 1.14–1.37 ng/mL 
difference; p < 0.0001).
In analyses of the full sample (men and 
women), adjusted for age, sex, NHANES 
wave, and ethnicity, mean levels of PFOA were Melzer et al.
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higher in men than in women (p < 0.0001), 
and we found significant differences among 
ethnic groups (Table 1). Individuals with more 
education had higher PFOA levels (p = 0.008). 
Increased alcohol consumption levels were also 
associated with higher PFOA concentrations 
(p < 0.0001). We found similar differences in 
PFOS concentrations. Mean levels of PFOS 
were higher in men (p < 0.0001), with sig-
nificant differences in levels between ethnic 
groups, and individuals with more education 
had higher PFOS levels (p = 0.008).
Eight individuals did not answer ques-
tions about thyroid disease, so the sample size 
for this analysis was n = 3,966, with 1,900 
men, and 2,066 women (Table 2). In women, 
overall (unweighted) reported (any) thyroid 
disease was n = 292, and the NHANES-
weighted but unadjusted prevalence was 
16.18%; in men, n = 69, and weighted preva-
lence, 3.06%. The study-weighted prevalence 
of current thyroid disease taking medica-
tion was necessarily lower (women, n = 163, 
9.89%; men, n = 46, 1.18%).
We computed population-weighted 
quartiles of PFOA and PFOS concentrations 
in men and women separately (Table 2). The 
highest quartile (Q4) of PFOA in women 
ranged from 5.7 to 123.0 ng/mL, and in 
men from 7.3 ng/mL to 45.9 ng/mL. Study-
weighted but unadjusted prevalences of current 
thyroid disease taking related medication in 
women varied across the quartiles but with wide 
CIs: Q1 = 8.14% (95% CI, 5.75–10.53%), 
Q4 = 16.19% (95% CI, 11.74–20.62%); 
in men, unadjusted prevalence rates were far 
lower throughout (prevalence = 2.27% in Q1 
and Q4). For PFOS the prevalence of treated 
thyroid disease ranged from 8.14% (Q1) to 
12.55% (Q4) in women and from 1.85% to 
3.89% in men.
In logistic regression models adjusting for 
age, ethnicity, and study year (Table 3), we 
found associations between PFOA quartiles and 
both definitions of thyroid disease in women. 
For logistic models additionally adjusted for 
educational status, BMI, smoking status, 
and alcohol consumption, these associations 
remained significant; for example, comparing 
those with PFOA concentrations ≥ 5.7 ng/mL 
(Q4) versus ≤ 2.6 ng/mL (Q1), the OR for 
current thyroid disease on medication was 1.86 
(95% CI, 1.12–3.09; p = 0.018). Comparing 
Q4 with the larger control group of PFOA 
≤ 4.0 ng/mL (Q1 and Q2) the estimated OR 
for treated thyroid disease was 2.24 (95% CI, 
1.38–3.65; p = 0.002). In men, we found a 
similar suggestive trend, but it narrowly missed 
significance: Comparing PFOA concentrations 
≥ 7.3 ng/mL (Q4) versus ≤ 5.2 ng/mL (Q1 
and Q2), the OR for treated disease was 2.12 
(95% CI, 0.93–4.82; p = 0.073).
For PFOS concentrations, in women ORs 
for disease trended in a similar direction but 
were far from significant. However, in men 
we found an association comparing those with 
PFOS concentrations ≥ 36.8 ng/mL (Q4) versus 
≤ 25.5 ng/mL (Q1 and Q2): OR for treated dis-
ease was 2.68 (95% CI, 1.03–6.98; p = 0.043).
Sensitivity analyses. For a sensitivity anal-
ysis, we computed a logistic regression model 
including both men and women, testing an 
interaction term between sex and PFOA lev-
els for treated thyroid disease risk. The inter-
action term was not significant (p-value for 
interaction = 0.152).
For a post hoc analysis, we examined 
associations between chemical concentration 
quartile and any of the other major disease 
categories covered in NHANES: arthritis, 
asthma, COPD, diabetes, heart disease, or 
Table 1. Survey-weighted characteristics of sample with survey-weighted back-transformed geometric mean concentrations (95% CIs) of PFOA and PFOS.
Men Women
Characteristic n (% within group) PFOA PFOS n (% within group) PFOA PFOS
Overall 1,900 (100) 4.91 (4.64–5.2) 25.08 (23.63–26.62) 2,066 (100) 3.77 (3.52–4.04) 19.14 (17.8–20.58)
Age (years)
20–49 928 (62.6) 5.30 (5.02–5.59) 24.2 (22.66–25.84) 1,134 (59.8) 3.38 (3.13–3.64) 16.72 (15.37–18.19)
50–69 553 (27.0) 4.46 (4.12–4.82) 26.97 (24.87–29.25) 545 (26.7) 4.62 (4.15–5.14) 22.92 (20.81–25.23)
≥ 70 419 (10.4) 3.99 (3.53–4.52) 25.8 (23.22–28.67) 387 (13.4) 4.13 (3.78–4.51) 24.39 (22.19–26.81)
Ethnicity
Mexican American 432 (8.3) 3.73 (3.48–4) 18.44 (16.79–20.25) 481 (7.3) 2.44 (2.21–2.7) 12.04 (10.91–13.29)
Other Hispanic 62 (4.2) 5.63 (4.77–6.65) 27.73 (21.89–35.14) 92 (5.9) 3.6 (3.17–4.09) 16.28 (14.29–18.56)
Non-Hispanic white 969 (73.5) 5.13 (4.83–5.45) 25.7 (24.04–27.47) 1,008 (71.8) 4.13 (3.84–4.45) 20.08 (18.57–21.72)
Non-Hispanic black 382 (9.9) 4.43 (3.92–5) 27 (24.3–30) 415 (10.8) 2.98 (2.66–3.34) 20.52 (17.97–23.42)
Other 55 (4.1) 4.32 (3.47–5.38) 22.77 (17.3–29.97) 70 (4.3) 3.3 (2.61–4.17) 19.64 (15.04–25.64)
Education
< High school 637 (20.9) 4.14 (3.82–4.49) 22.08 (20.47–23.82) 628 (19.5) 3.53 (3.11–4) 19.26 (17.1–21.69)
High school graduate 478 (29.3) 4.94 (4.56–5.35) 25.22 (23.56–27) 498 (25.9) 4 (3.69–4.34) 19.9 (18.15–21.83)
> High school 782 (49.7) 5.26 (4.93–5.62) 26.38 (24.54–28.36) 937 (54.6) 3.76 (3.49–4.04) 18.74 (17.32–20.28)
Unknown 3 (0.0) 2.22 (1.31–3.74) 17.59 (8.5–36.41) 3 (0.0) 1.84 (1.32–2.56) 12.64 (7.25–22.02)
BMI
0–18.5 23 (1.2) 4.42 (2.78–7.01) 17.95 (10.79–29.87) 35 (2.4) 3.78 (3.07–4.65) 18.39 (14.05–24.08)
18.5–25 525 (28.8) 4.89 (4.44–5.39) 24.36 (21.99–26.98) 594 (32.6) 3.84 (3.52–4.19) 18.97 (17.53–20.52)
25–30 778 (39.8) 5.01 (4.67–5.38) 25.28 (23.55–27.13) 615 (27.8) 3.64 (3.3–4.01) 19.48 (17.86–21.24)
≥ 30 545 (29.0) 4.9 (4.54–5.29) 26.28 (24.42–28.28) 784 (36.0) 3.83 (3.49–4.2) 19 (17–21.22)
Unknown 29 (1.2) 3.1 (2.23–4.3) 17.51 (10.34–29.66) 38 (1.2) 3.36 (2.78–4.05) 21.81 (17.13–27.78)
Smoking status
Smoked < 100 cigarettes in lifetime 761 (41.1) 5.01 (4.68–5.37) 26.16 (24.19–28.29) 1,300 (58.6) 3.63 (3.36–3.93) 18.91 (17.43–20.52)
Former smoker 664 (30.0) 4.67 (4.28–5.09) 25.66 (23.7–27.79) 417 (21.3) 3.81 (3.46–4.19) 19.22 (17.33–21.32)
Some days 90 (4.8) 5.12 (4.23–6.19) 21.33 (17.97–25.31) 46 (2.4) 4.05 (3.36–4.89) 18.29 (15.06–22.22)
Every day 385 (24.1) 5.01 (4.7–5.33) 23.43 (21.45–25.59) 302 (17.8) 4.17 (3.73–4.67) 19.9 (17.76–22.29)
Unknown 1 (0.0)
Average drinks per day in previous 12 months
Nondrinker 334 (15.8) 4.44 (3.89–5.06) 25.38 (22.78–28.28) 857 (35.1) 3.5 (3.22–3.8) 18.84 (16.81–21.11)
1 298 (15.7) 4.67 (4.22–5.17) 26.39 (23.19–30.02) 316 (17.9) 3.87 (3.47–4.32) 20.37 (18.12–22.9)
2 282 (17.5) 5.4 (4.86–6.01) 27.7 (24.76–30.99) 291 (18.0) 4.15 (3.79–4.55) 19.82 (17.95–21.87)
3 181 (11.1) 5.2 (4.79–5.65) 23.73 (21.2–26.56) 124 (6.6) 3.82 (3.4–4.29) 18.07 (15.81–20.65)
4 97 (6.0) 5.58 (4.94–6.31) 25.05 (21.27–29.5) 64 (3.3) 3.96 (3.19–4.92) 15.71 (12.89–19.14)
≥ 5 283 (16.4) 5.25 (4.88–5.65) 23.09 (20.92–25.49) 80 (4.8) 4.63 (3.62–5.91) 18.13 (14.76–22.27)
Unknown 425 (17.6) 4.44 (4.07–4.84) 24.04 (21.44–26.96) 334 (14.4) 3.58 (3.22–3.98) 19.26 (17.29–21.46)PFOA and thyroid disease
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liver disease. Combining men and women (to 
reduce multiple testing and because these dis-
eases are less sex related), we found no signifi-
cant associations for PFOA (Table 4) except 
for comparisons between the intermediate 
quartiles and Q1 for arthritis, but this did not 
reach significance in the top quartile.
For PFOS, we found no “positive” asso-
ciations between higher serum concentrations 
and higher prevalence of disease. We found 
one statistically significant “negative” associa-
tion suggesting that people reporting having 
COPD may be less likely to be in the highest 
PFOA concentration quartile (OR = 0.58; 
95% CI, 0.43–0.76; p = 0.0003).
Table 2. Sex-specific summary statistics with thyroid disease prevalence by weighted (95% CIs) quartile of PFOA and PFOS.
Summary statistics by quartile Thyroid disease ever Current thyroid disease with thyroid medication
n
Range  
(ng/mL)
Mean ± SD 
(ng/mL)
Weighted mean  
(95% CI) (ng/mL)
n Prevalence (%) n Prevalence (%)
(case/total) Unweighted Weighted (case/total) Unweighted Weighted
Women
PFOA
All 2,066 0.1–123.0 4.25 ± 4.92 4.84 (4.35–5.33) 292/2,066 14.13 16.18 (14.44–18.09) 163/2,066 7.89 9.89 (8.32–11.72)
Q1 689 0.1–2.6 1.71 ± 0.66 1.79 (1.72–1.85) 65/689 9.43 12.62 (9.66–15.57) 34/689 4.93 8.14 (5.75–10.53)
Q2 550 2.7–4.0 3.32 ± 0.40 3.33 (3.28–3.38) 71/550 12.91 13.87 (9.66–18.08) 35/550 6.36 7.27 (4.37–10.16)
Q3 441 4.1–5.7 4.79 ± 0.48 4.78 (4.72–4.85) 72/441 16.33 15.98 (11.81–20.15) 39/441 8.84 8.25 (4.97–11.52)
Q4 386 5.7–123.0 9.47 ± 9.38 9.7 (8.43–10.98) 84/386 21.76 22.57 (17.44–27.71) 55/386 14.25 16.18 (11.74–20.62)
PFOS
All 2,066 0.14–406.0 23.24 ± 23.13 24.78 (22.6–26.9) 292/2,066 14.13 16.18 (14.44–18.09) 163/2,066 7.89 9.89 (8.32–11.72)
Q1 616 0.14–12.4 8.13 ± 2.82 8.49 (8.06–8.93) 68/616 11.04 15.14 (10.82–19.46) 32/616 5.19 8.7 (5.45–11.96)
Q2 523 12.5–19.4 15.75 ± 2.02 15.92 (15.71–16.13) 71/523 13.58 16.23 (12.58–19.89) 40/523 7.65 9.85 (6.58–13.13)
Q3 466 19.5–29.8 24.21 ± 2.89 24.49 (24.03–24.94) 62/466 13.30 12.69 (8.59–16.78) 39/466 8.37 8.47 (4.98–11.97)
Q4 461 29.9–406.0 50.96 ± 35.15 50.48 (45.81–55.16) 91/461 19.74 20.66 (16.46–24.87) 52/461 11.28 12.55 (8.86–16.23)
Men 
PFOA
All 1,900 0.1–45.9 5.23 ± 3.41 5.79 (5.41–6.18) 69/1,900 3.63 3.06 (2.40–3.88) 46/1,900 2.42 1.88 (1.30–2.69)
Q1 643 0.1–3.6 2.47 ± 0.85 2.51 (2.43–2.58) 24/643 3.73 3.49 (2.01–4.97) 16/643 2.49 2.27 (1.25–3.30)
Q2 517 3.7–5.2 4.42 ± 0.45 4.44 (4.39–4.50) 20/517 3.87 3.44 (1.48–5.41) 13/517 2.51 2.14 (0.79–3.49)
Q3 381 5.3–7.2 6.12 ± 0.55 6.19 (6.12–6.26) 11/381 2.89 1.51 (0.38–2.63) 7/381 1.84 0.77 (0.17–1.37)
Q4 359 7.3–45.9 10.39 ± 4.20 10.3 (9.72–10.89) 14/359 3.90 3.71 (1.67–5.75) 10/359 2.79 2.27 (0.22–4.33)
PFOS
All 1,900 0.3–435.0 29.57 ± 22.11 30.36 (28.2–32.5) 69/1,900 3.63 3.06 (2.40–3.88) 46/1,900 2.42 1.88 (1.30–2.69)
Q1 529 0.3–18.0 12.29 ± 4.30 12.35 (11.94–12.76) 18/529 3.40 3.22 (1.86–4.57) 10/529 1.89 1.85 (0.82–2.89)
Q2 480 18.2–25.5 21.82 ± 2.13 21.83 (21.63–22.03) 13/480 2.71 1.64 (0.40–2.87) 8/480 1.67 0.80 (0.12–1.48)
Q3 454 25.6–36.7 30.81 ± 3.18 30.93 (30.57–31.29) 15/454 3.30 2.68 (1.26–4.10) 11/454 2.42 1.62 (0.55–2.69)
Q4 437 36.8–435.0 57.73 ± 29.4 56.45 (52.85–60.04) 23/437 5.26 4.69 (2.44–6.95) 17/437 3.89 3.24 (1.07–5.40)
Quartiles (Q1–Q4) reflect the U.S. population, accounting for population weighting in NHANES. 
Table 3. Sex-specific, survey-weighted associations between PFOA and PFOS concentrations and thyroid disease [OR (95% CI), p-value].
PFOA PFOS
Group/quartile
Models adjusting for age, 
ethnicity, and study year Fully adjusted modelsa
Models adjusting for age, 
ethnicity, and study year Fully adjusted modelsa
Women
Thyroid disease ever
Q1 1 1 1 1
Q2 0.98 (0.65–1.50), p = 0.936 0.95 (0.62–1.47), p = 0.825 1.04 (0.63–1.71), p = 0.875 1.01 (0.63–1.6), p = 0.972
Q3 1.09 (0.66–1.81), p = 0.729 1.11 (0.67–1.83), p = 0.679 0.68 (0.4–1.17), p = 0.155 0.64 (0.39–1.05), p = 0.078
Q4 1.63 (1.07–2.47), p = 0.024* 1.64 (1.09–2.46), p = 0.019* 1.11 (0.66–1.86), p = 0.69 1.15 (0.7–1.91), p = 0.568
Q4 vs. Q1 and Q2 1.64 (1.12–2.41), p = 0.013* 1.68 (1.14–2.49), p = 0.011* 1.08 (0.73–1.61), p = 0.681 1.15 (0.78–1.7), p = 0.48
Thyroid disease current with medication
Q1 1 1 1 1
Q2 0.77 (0.45–1.32), p = 0.334 0.7 (0.41–1.22), p = 0.205 1.11 (0.58–2.14), p = 0.747 1.05 (0.55–2), p = 0.89
Q3 0.86 (0.47–1.57), p = 0.607 0.89 (0.49–1.59), p = 0.676 0.85 (0.46–1.59), p = 0.609 0.81 (0.44–1.51), p = 0.496
Q4 1.83 (1.13–2.95), p = 0.015* 1.86 (1.12–3.09), p = 0.018* 1.27 (0.69–2.32), p = 0.435 1.31 (0.72–2.36), p = 0.369
Q4 vs. Q1 and Q2 2.09 (1.34–3.26), p = 0.002* 2.24 (1.38–3.65), p = 0.002* 1.19 (0.77–1.85), p = 0.417 1.27 (0.82–1.97), p = 0.269
Men
Thyroid disease ever
Q1 1 1 1 1
Q2 1.17 (0.64–2.15), p = 0.600 1.11 (0.62–1.99), p = 0.729 0.50 (0.22–1.17), p = 0.107 0.51 (0.23–1.14), p = 0.097
Q3 0.58 (0.21–1.59), p = 0.283 0.57 (0.19–1.66), p = 0.291 0.81 (0.40–1.61), p = 0.536 0.88 (0.43–1.84), p = 0.736
Q4 1.58 (0.79–3.16), p = 0.191 1.58 (0.74–3.39), p = 0.233 1.51 (0.70–3.22), p = 0.284 1.58 (0.72–3.47), p = 0.251
Q4 vs. Q1 and Q2 1.45 (0.68–3.09), p = 0.323 1.5 (0.66–3.39), p = 0.324 1.6 (0.57–4.46), p = 0.360 1.78 (0.58–5.52), p = 0.309
Thyroid disease current with medication
Q1 1 1 1 1
Q2 1.18 (0.55–2.54), p = 0.668 1.12 (0.52–2.39), p = 0.767 0.42 (0.16–1.10), p = 0.077 0.43 (0.17–1.08), p = 0.073
Q3 0.51 (0.20–1.32), p = 0.162 0.49 (0.18–1.38), p = 0.171 0.82 (0.29–2.27), p = 0.694 0.95 (0.34–2.70), p = 0.926
Q4 1.74 (0.63–4.78), p = 0.275 1.89 (0.60–5.90), p = 0.268 1.72 (0.73–4.05), p = 0.211 1.89 (0.72–4.93), p = 0.190
Q4 vs. Q1 and Q2 2.02 (0.89–4.58), p = 0.092 2.12 (0.93–4.82), p = 0.073 2.44 (1.04–5.74), p = 0.041* 2.68 (1.03–6.98), p = 0.043*
aModels adjusted for age, ethnicity, education, BMI, smoking status, and alcohol consumption. *p < 0.05. Melzer et al.
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Discussion
In this study we aimed to determine whether 
increased serum PFOA or PFOS concentra-
tions were associated with thyroid disease 
in a general adult U.S. population sample. 
The prevalence of thyroid disease is markedly 
higher in women than in men, so we esti-
mated sex-specific associations. We found that, 
across all the available data from NHANES, 
thyroid disease associations with serum PFOA 
concentrations are present in women and are 
strongest for those currently being treated for 
thyroid disease. In men, we also found a near 
significant association between PFOA and 
treated thyroid disease. An interaction term 
analysis suggests that the PFOA trends in men 
and women are not significantly different, 
despite the relative rarity of thyroid disease 
in men. In addition, we found a nominally 
significant association between PFOS concen-
trations and treated thyroid disease in men but 
not in women.
The presence of associations with both 
PFOA and PFOS raises the issue of how best 
to perform risk assessments for combinations 
of perfluorochemicals. The somewhat diver-
gent risk patterns for the two compounds sup-
port their separate risk assessment (Scialli et al. 
2007), given that current legislative advice 
(Minnesota Department of Health 2008) is 
to consider the combined effects of chemicals 
only when two or more chemicals in a mixture 
affect the same tissue, organ, or organ system.
Our results are important because PFAAs 
are detectable in virtually everyone in soci-
ety (Kannan et al. 2004), with ubiquitous 
presence across global populations (Calafat 
et al. 2006). Occupational exposure to PFOA 
reported in 2003 showed mean serum values 
of 1,780 ng/mL (range, 40–10,060 ng/mL) 
(Olsen et al. 2003a) and 899 ng/mL (range, 
722–1,120 ng/mL) (Olsen et al. 2003c). 
Production of PFOS was halted in 2002 in 
the United States by its principal producer, 
due largely to concerns over bioaccumulation 
and toxicity. Since then, voluntary industry 
reductions in production and use of other per-
fluorinated compounds, such as the U.S. EPA–
initiated PFOA Stewardship Program (U.S. 
EPA 2006), have contributed to a decreasing 
trend in human exposure for all perfluorinated 
compounds (with the notable exception of 
perfluorononanoic acid) (Calafat et al. 2007; 
Olsen et al. 2007). In May 2009, PFOS was 
listed under the Stockholm Convention on 
Persistent Organic Pollutants (2008).
Our results can be compared with previous 
studies of human populations and of nonhu-
man primates. A 6-month study of cynomol-
gus monkeys chronically exposed to PFOA 
showed no associations between PFOA and 
thyroid parameters, at mean serum PFOA 
concentrations higher than those reported in 
NHANES, although only male monkeys were 
involved (Butenhoff et al. 2002). The largest 
human study of PFOA centers on an indus-
trial facility in Washington, West Virginia, 
from which PFOA spread to the population 
through air, water, occupational, and domes-
tic exposure in a point-source contamina-
tion. The C8 Health Project (Steenland et al. 
2009) has measured PFOA concentrations in 
> 69,000 residents. Markedly high concentra-
tions were found, with an arithmetic mean of 
83 ng/mL and a median concentration in serum 
of 28 ng/mL (C8 Science Panel 2008), far 
higher than the NHANES concentrations in the 
general population. Preliminary analyses report 
associations between PFOA and total choles-
terol, low-density lipoproteins, and triglyceride 
concentrations in multivariate models adjusting 
for age, BMI, sex, education, smoking, alco-
hol, and regular exercise. Comprehensive cross-
sectional and follow-on analyses of associations 
with thyroid disease have not yet been reported 
but are expected to be released in 2010–2011 
(C8 Science Panel 2009).
Importantly, disruption to thyroid hor-
mone balance was not found in other studies of 
populations exposed to PFOA, despite the con-
siderably higher levels reported in some stud-
ies (Emmett et al. 2006; Olsen et al. 2003b). 
Emmett et al. (2006) studied 371 residents of a 
Table 4. Associations between PFOA and PFOS concentrations (population-based quartiles) and other diseases in fully adjusted logistic regression models (by 
self-reported disease status).
PFOA PFOS
Disease/quartile n (% survey-weighted) OR (95% CI) p-Value n (% survey-weighted) OR (95% CI) p-Value
Arthritis ever 1,006/3,960 (22.8) 1,006/3,960 (22.8)
Q1 287/1,310 (19.2) 1 1 219/1,132 (19.0) 1 1
Q2 298/1,036 (27.6) 1.63 (1.24–2.14) 0.001 267/1,009 (23.5) 1.19 (0.91–1.54) 0.193
Q3 231/857 (22.7) 1.31 (1.03–1.66) 0.029 260/916 (26.8) 1.29 (1.00–1.66) 0.054
Q4 190/757 (21.8) 1.28 (0.97–1.68) 0.082 260/903 (22.0) 0.74 (0.53–1.04) 0.085
Asthma ever 471/3,961 (13.2) 471/3,961 (13.2)
Q1 138/1,313 (11.9) 1 1 139/1,133 (14.0) 1 1
Q2 128/1,036 (14.2) 1.25 (0.92–1.70) 0.154 140/1,013 (15.6) 1.16 (0.80–1.68) 0.427
Q3 122/856 (15.8) 1.44 (1.01–2.05) 0.045 111/914 (13.1) 0.97 (0.65–1.43) 0.867
Q4 83/756 (11.2) 0.93 (0.64–1.36) 0.716 81/901 (10.3) 0.79 (0.50–1.26) 0.320
COPD ever 302/3,953 (8.2) 302/3,953 (8.2)
Q1 81/1,310 (7.7) 1 1 83/1,131 (8.8) 1 1
Q2 93/1,033 (8.8) 0.91 (0.58–1.43) 0.677 85/1,008 (8.5) 0.84 (0.56–1.25) 0.384
Q3 66/853 (8.3) 0.88 (0.54–1.43) 0.593 67/914 (7.7) 0.67 (0.41–1.09) 0.103
Q4 62/757 (8.2) 0.85 (0.54–1.34) 0.473 67/900 (7.9) 0.58 (0.43–0.76) 0.0003
Diabetes ever 459/3,964 (8.7) 459/3,964 (8.7)
Q1 186/1,314 (10.9) 1 1 122/1,133 (8.6) 1 1
Q2 127/1,035 (9.2) 0.80 (0.55–1.17) 0.242 119/1,012 (9.3) 1.02 (0.70–1.47) 0.928
Q3 83/857 (7.7) 0.74 (0.48–1.15) 0.177 103/916 (7.7) 0.76 (0.50–1.18) 0.218
Q4 63/758 (7.0) 0.69 (0.41–1.16) 0.158 115/903 (9.4) 0.87 (0.57–1.31) 0.491
Heart disease evera 321/3,966 (5.8) 321/3,966 (5.8)
Q1 93/1,314 (5.7) 1 1 69/1,134 (4.8) 1 1
Q2 93/1,037 (6.1) 0.95 (0.59–1.51) 0.816 85/1,013 (5.1) 0.77 (0.49–1.23) 0.270
Q3 78/857 (5.9) 1.02 (0.65–1.61) 0.917 80/916 (5.7) 0.83 (0.46–1.51) 0.540
Q4 57/758 (5.4) 1.08 (0.70–1.69) 0.715 87/903 (7.4) 0.91 (0.50–1.64) 0.745
Liver disease current 57/3,942 (1.4) 57/3,942 (1.4)
Q1 24/1,307 (1.4) 1 1 22/1,127 (1.7) 1 1
Q2 11/1,028 (1.0) 0.66 (0.25–1.74) 0.391 10/1,007 (0.9) 0.49 (0.18–1.32) 0.154
Q3 17/855 (2.5) 1.93 (0.96–3.88) 0.065 13/910 (1.6) 0.94 (0.41–2.16) 0.880
Q4 5/752 (0.8) 0.61 (0.21–1.78) 0.355 12/898 (1.5) 0.95 (0.39–2.29) 0.907
aAny report of coronary heart disease, and/or angina, and/or heart attack.PFOA and thyroid disease
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community with long-standing environmental 
exposure to PFOA and found a median serum 
PFOA concentration of 181–571 ng/mL but 
no association between serum PFOA and a his-
tory of thyroid disease. A study that included 
thyroid hormone levels reported a positive asso-
ciation between serum PFOA concentration 
and T3 levels in occupationally exposed work-
ers, although there were no changes in other 
thyroid hormones (Olsen et al. 2001). Modest 
associations between PFOA and thyroid hor-
mones (negative for free T4 and positive for 
T3) were reported in 506 PFOA production 
workers across three production facilities 
(Olsen and Zobel 2007); there were no asso-
ciations between TSH or T4 and PFOA, and 
the free hormone levels were within the normal 
  reference range.
A linear extrapolation of the findings 
reported here would be expected to lead to 
associations being more evident at higher 
exposure levels, yet this is not supported by 
the literature. Nonlinearity of response is not 
uncommon for receptor-mediated systems 
such as endocrine-signaling pathways that act 
to amplify the original signal. Large changes 
in cell function can occur in response to 
extremely low concentrations, but which may 
become saturated and hence unresponsive at 
higher concentrations (vom Saal and Hughes 
2005; Welshons et al. 2003).
The mechanisms involved in thyroid 
homeostasis are numerous and complex, 
and there are multiple potential targets for 
disruption of thyroid hormone homeostasis 
(Schmutzler et al. 2007). These include thy-
rotropin receptor (Santini et al. 2003), iodine 
uptake by the sodium iodide transporter 
(Schröder van der Elst et al. 2003), type 1 
5´-deiodinase (Ferreira et al. 2002), trans-
thyretin (Kohrle et al. 1988), thyroid hor-
mone receptor (Moriyama et al. 2002), and 
the thyroid hormone–dependent growth of 
pituitary cells (Ghisari and Bonefeld-Jorgensen 
2005). Depression of serum T4 and T3 has 
been reported by several authors in PFOS-
exposed rats (Lau et al. 2003; Luebker et al. 
2005; Seacat et al. 2003). One mechanism 
by which PFAAs may deplete T4 is through 
induction of the hepatic uridine diphospho-
glucuronosyl transferase (UGT) system, which 
is involved in hepatic metabolism of thy-
roid hormone and biliary clearance of T4 as 
T4-glucuronide (Barter and Klaassen 1994). 
Because PFOA is an agonist for PPARα, it 
is plausible that induction of hepatic UGT 
in PFAA-exposed rats (Yu et al. 2009) could 
represent a PPARα-mediated response. The 
involvement of another PPARα agonist, 
WY 14643, in enhancing the hepatic degra-
dation of thyroid hormone has recently been 
shown (Weineke et al. 2009).
A growing body of data describes the 
in vitro binding affinity of PFOA to human 
serum-binding proteins (Chen and Guo 2009) 
and to PPARα, -β, and -γ and other nuclear 
receptors (Vanden Huevel et al. 2006), but the 
contribution of these mechanisms to PFOA’s 
thyroid-mediating effects in humans remains 
to be established. Many cellular and metabolic 
processes, including lipid metabolism, energy 
homeostasis, and cell differentiation, are con-
trolled by PPARα. Early studies of the effects 
of PFAAs in rodents showed that a single dose 
lowered heart rate and body temperature and 
depressed T4 and T3. Replacement of T4 did 
not reverse the clinical symptoms of hypo-
thermia (Gutshall et al. 1988; Langley and 
Pilcher 1985). Although circulating thyroid 
hormone levels were low, liver enzymes respon-
sive to thyroid hormone levels were elevated, 
suggesting that thyroidal homeostasis was 
not functionally compromised. Chang et al. 
(2007) found that exposure to PFOS for up to 
3 weeks did not affect functional thyroid sta-
tus, because free T4, TSH, and various thyroid-
responsive liver enzymes were all unaffected. 
These findings and later results have led to 
proposals that displacement of circulating thy-
roid hormones from plasma protein-binding 
sites and a reduced responsiveness of the HPT 
axis contribute significantly towards PFOA’s 
hypothyroid-inducing effects (Lau et al. 2007). 
Whatever the mechanisms involved, it is clear 
that more research is merited to clarify the 
pathways involved.
The feedback mechanism by which the rate 
of release of TSH and the circulating levels of 
T3 and T4 are regulated tends to show a low 
level of individual variation (Felt-Rasmussen 
et al. 1980). Therefore, subtle disruption of 
the HPT axis within normal reference ranges 
may have negative health consequences for 
the individual while remaining within normal 
reference values, highlighting the importance 
of including both clinical and laboratory end 
points in such studies. The NHANES data 
do not allow specification of the precise type 
of thyroid disease present, because NHANES 
does not report on individual hormone levels. 
PFOA concentration was positively associated 
with free T4 and negatively associated with 
T3 levels in a cohort of 506 exposed workers, 
with a near significant association with TSH 
levels (Olsen et al. 2007), although all effects 
were regarded as modest.
The limitations of these analyses should 
be noted. We based the PFOA and PFOS 
measures on a single serum sample. Although 
PFOA has a half-life of 4 years (Olsen et al. 
2007), so a single sample is likely to represent 
medium-term internal dose, samples taken at 
several time points might be more accurate 
in classifying exposure. Any misclassification 
from single measures would tend to decrease 
power and underestimate the real strengths 
of association. Second, the PFOA concen-
trations were measured at the same time as 
disease status, making attribution of causal 
direction difficult. This raises the possibility 
of reverse causation. One might hypothesize 
that after onset of thyroid disease, changes 
in the nature of exposure or in the pharma-
cokinetics of PFOA might occur [including 
patterns of absorption, distribution (including 
protein binding) or excretion]. Because the 
associations we report were present in people 
who were on thyroid hormone replacements, 
which effectively mimic normal thyroid 
function, a mechanism for reverse causation 
through changes in pharmacokinetics is diffi-
cult to imagine. Confounding by unmeasured 
factors is also possible, but it is unlikely that 
confounding could explain similar findings 
reported from some of the diverse experimen-
tal and observational studies discussed above.
Post hoc association testing with other 
common diseases (necessarily involving mul-
tiple statistical testing) did not identify other 
robust associations of higher PFC concentra-
tion with increased disease prevalence, sug-
gesting specificity of our findings for thyroid 
disease. An apparent association between 
higher PFOS concentrations and lower preva-
lence of COPD requires replication, to exclude 
a false-positive result from multiple testing. 
In addition to the limitations of our 
analyses, the strengths should also be noted: 
This is the first large-scale analysis in a nation-
ally representative general adult population 
of directly measured serum concentrations 
of PFOA and PFOS. In addition, the asso-
ciations present are strongest for the most 
specific identification of thyroid disease, based 
on reported diagnosis with current use of 
thyroid-specific medication. The NHANES 
study also supported adjustment of models 
for a range of potential confounding factors, 
which in fact made relatively minor differ-
ences to the key estimates, suggesting that the 
associations are robust.
Further work is clearly needed to char-
acterize the PFOA and PFOS associations 
with specific thyroid diagnoses and thyroid 
hormone levels in the general population 
and to clarify whether the associations reflect 
pathology, changes in exposure, or altered 
pharmacokinetics. Longitudinal analyses are 
also needed to establish whether high expo-
sures predict future onsets of thyroid disease, 
although concurrent alteration of thyroid 
functioning would still be a cause for concern.
Conclusions
Higher PFOA and PFOS concentrations are 
associated with thyroid disease (and being on 
thyroid-related medication) in the NHANES 
U.S. general adult population representa-
tive study samples. More work is needed to 
establish the mechanisms underlying this 
association and to exclude confounding and 
pharmacokinetic explanations.Melzer et al.
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